RA Capital Healthcare Fund LP Sells Over $10 Million in Vor Biopharma Shares
Summary
RA Capital Healthcare Fund LP, a 10% owner and director, reported selling an additional $10.2 million worth of Vor Biopharma common stock in open market transactions between April 8 and April 10, 2026.
Key Events
-
Significant Insider Sale
RA Capital Healthcare Fund LP, a 10% owner and director, disposed of 620,133 shares of Vor Biopharma common stock for a total value of $10,233,811 across four transactions.
-
Continuation of Selling Trend
These sales occurred between April 8 and April 10, 2026, following a previous sale of over $14.5 million by the same entity reported on April 6, 2026, indicating a sustained reduction in holdings.
-
Post-Transaction Holdings
Following these transactions, RA Capital Healthcare Fund LP's indirect holdings in Vor Biopharma stand at 3,935,608 shares.
Analysis
RA Capital Healthcare Fund LP, a significant institutional investor and board member, has continued to reduce its stake in Vor Biopharma. This sale of over $10 million in shares, following a previous disposition of $14.5 million reported just days prior, indicates a sustained reduction in exposure. While such sales by financial investors can be for portfolio rebalancing, the substantial value of these transactions, especially in the context of Vor Biopharma's recently reported $696.0 million net loss and negative equity for 2025, could signal a lack of conviction or a strategic shift away from the company. Investors should note the cumulative selling pressure from this key insider.
At the time of this filing, VOR was trading at $15.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $755.7M. The 52-week trading range was $2.62 to $65.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.